AnaptysBio Inc (ANAB)
21.17
+0.86
(+4.23%)
USD |
NASDAQ |
Nov 21, 16:00
21.18
+0.02
(+0.07%)
After-Hours: 20:00
AnaptysBio Profit Margin (Quarterly): -109.4% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -109.4% |
| June 30, 2024 | -425.3% |
| March 31, 2024 | -612.0% |
| December 31, 2023 | -468.8% |
| September 30, 2023 | -1.12K% |
| June 30, 2023 | -1.15K% |
| March 31, 2023 | -3.22K% |
| December 31, 2022 | -388.0% |
| September 30, 2022 | -2.59K% |
| June 30, 2022 | -2.68K% |
| March 31, 2022 | -3.74K% |
| December 31, 2021 | -3.22K% |
| September 30, 2021 | -31.91% |
| June 30, 2021 | -1.43% |
| March 31, 2021 | -161.5% |
| December 31, 2020 | 56.08% |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -55.08% |
| December 31, 2019 | -675.4% |
| September 30, 2019 |
| Date | Value |
|---|---|
| June 30, 2019 | -479.2% |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | -319.2% |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | -228.7% |
| September 30, 2017 | |
| June 30, 2017 | -38.34% |
| March 31, 2017 | |
| December 31, 2016 | -166.2% |
| September 30, 2016 | -34.69% |
| June 30, 2016 | 39.69% |
| March 31, 2016 | -18.25% |
| December 31, 2015 | -86.63% |
| September 30, 2015 | -32.22% |
| June 30, 2015 | -1.13% |
| March 31, 2015 | -9.18% |
| December 31, 2014 | 13.55% |
| September 30, 2014 | 56.19% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-3.74K%
Minimum
Mar 2022
56.08%
Maximum
Dec 2020
-1.14K%
Average
-540.4%
Median
Profit Margin (Quarterly) Benchmarks
| Eli Lilly and Co | 8.48% |
| Regeneron Pharmaceuticals Inc | 36.03% |
| Ligand Pharmaceuticals Inc | -13.84% |
| Agios Pharmaceuticals Inc | -- |
| ADMA Biologics Inc | 29.96% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -236.3% |
| Return on Assets | -36.55% |
| Return on Invested Capital | -236.3% |
| Operating Margin (Quarterly) | -75.81% |
| Return on Net Operating Assets | -652.6% |